NasdaqGM:WVEPharmaceuticals
Wave Life Sciences (WVE) Is Up 11.7% After Early WVE-007 Fat-Loss Data - What's Changed
In December 2025, Wave Life Sciences reported interim Phase 1 INLIGHT data for its investigational siRNA therapy WVE-007, showing meaningful reductions in visceral and total body fat and increases in lean mass after a single 240 mg dose in metabolic disease patients.
Because WVE-007’s early results suggest simultaneous fat loss and lean mass preservation, it may address an important limitation of many existing obesity treatments.
Next, we’ll explore how this early WVE-007 efficacy and safety...